High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)

JTO Clinical and Research Reports · Elsevier

Аннотация

Publication date: November 2026 Source: JTO Clinical and Research Reports, Volume 7, Issue 11 Author(s): Yoshihiko Sakata, Kenta Murotani, Daichi Fujimoto, Yukihiro Toi, Toshihide Yokoyama, Seigo Katakura, Teppei Yamaguchi, Kaoru Tanaka, Satoru Miura, Motohiro Tamiya, Motoko Tachihara, Takehito Shukuya, Yuko Tsuchiya, Yuki Sato, Satoshi Ikeda, Shinya Sakata, Takeshi Masuda, Shinnosuke Takemoto, Hirotsugu Kenmotsu, Isamu Okamoto

Читать у издателя →

Похожие статьи